Durect Reports Positive Phase IIb Results For Posidur In Post-Op Hernia Pain
Posidur, co-developed with Nycomed, has the potential to become a more than $2 billion opportunity, Durect CFO tells “The Pink Sheet” DAILY.
Posidur, co-developed with Nycomed, has the potential to become a more than $2 billion opportunity, Durect CFO tells “The Pink Sheet” DAILY.